Oncotelic Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncotelic Therapeutics, Inc.
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval
Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.
Ring Therapeutics Turns To Anelloviruses To Disrupt Gene Therapy Space
Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
- Large Molecule
- Other Names / Subsidiaries
- Mateon Therapeutics, Inc.
- OXiGENE, Inc.
- PointR Data, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.